These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24736920)

  • 1. Improving AEFI surveillance in India.
    Mahajan V; Saini SS
    Indian Pediatr; 2014 Mar; 51(3):233. PubMed ID: 24736920
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse event following immunization (AEFI) surveillance in India, position paper of Indian Academy of Pediatrics,2013.
    Chitkara AJ; Thacker N; Vashishtha VM; Bansal CP; Gupta SG
    Indian Pediatr; 2013 Aug; 50(8):739-41. PubMed ID: 24036641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization safety in US print media, 1995-2005.
    Hussain H; Omer SB; Manganello JA; Kromm EE; Carter TC; Kan L; Stokley S; Halsey NA; Salmon DA
    Pediatrics; 2011 May; 127 Suppl 1():S100-6. PubMed ID: 21502237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience.
    Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
    Expert Rev Vaccines; 2018 Jun; 17(6):555-562. PubMed ID: 29865876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine pharmacovigilance in India: Current context and future perspective.
    Meher BR
    Indian J Pharmacol; 2019; 51(4):243-247. PubMed ID: 31571710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direction of National Vaccine Program and role of adverse events following immunization.
    Win S
    Southeast Asian J Trop Med Public Health; 2014; 45 Suppl 1():40-2. PubMed ID: 25423787
    [No Abstract]   [Full Text] [Related]  

  • 8. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
    Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
    Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety reporting in developing country vaccine clinical trials-a systematic review.
    Muehlhans S; Richard G; Ali M; Codarini G; Elemuwa C; Khamesipour A; Maurer W; Mworozi E; Kochhar S; Rundblad G; Vuitton D; Rath B
    Vaccine; 2012 May; 30(22):3255-65. PubMed ID: 22406279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 11. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization.
    Kohl KS; Magnus M; Ball R; Halsey N; Shadomy S; Farley TA
    Vaccine; 2008 Nov; 26(50):6349-60. PubMed ID: 18805456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
    Guo B; Page A; Wang H; Taylor R; McIntyre P
    Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance of adverse events following immunization in Minhang district of Shanghai from 2007 to 2010].
    Zhang LP; Yu F; Jin BF; Wang Y; Xu HL; DU Y
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):859-64. PubMed ID: 23302620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone "beep" in a Cameroon health district: a randomized field trial.
    Tsafack M; Ateudjieu J
    Pan Afr Med J; 2015; 22():351. PubMed ID: 26985269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).
    Bonhoeffer J; Kohl K; Chen R; Duclos P; Heijbel H; Heininger U; Jefferson T; Loupi E
    Vaccine; 2002 Dec; 21(3-4):298-302. PubMed ID: 12450705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.